Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Published August 22, 2026 · Category: Finance

Overview

Robert I. Blum, President & CEO of Cytokinetics (NASDAQ:CYTK), reported the sale of 7,500 shares on Aug. 10, 2026, as disclosed in a recent SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average sale price ($76.76); post-transaction value based on Aug. 10, 2026, market close ($77.49).

Details

Cytokinetics is a clinical-stage biopharmaceutical company with a market capitalization of $10.6 billion, leveraging its proprietary muscle modulation platform to develop innovative cardiac therapeutics. The company has achieved commercial traction with MYQORZO while maintaining a robust pipeline of muscle-targeted candidates designed to address significant unmet medical needs in cardiology. With a strategic focus on cardiac indications, Cytokinetics positions itself at the intersection of precision medicine and cardiovascular treatment innovation.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Institutional Investors Are Buying Hyperliquid Strategies. Should You?
• This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.
• What Would Alan Greenspan Say About This Stock Market?